NYSE:ZTS

Zoetis (ZTS) Stock Forecast, Price & News

$163.01

+2.07 (+1.29%)

(As of 05/31/2023 ET)

Compare

Today's Range: $158.65
▼
$163.32
50-Day Range: $161.00
▼
$186.23
52-Week Range: $124.15
▼
$187.82

Volume: 5.31 million shs
Average Volume: 2.03 million shs
Market Capitalization: $75.33 billion

P/E Ratio: 36.80
Dividend Yield: 0.92%
Price Target: $221.14

Zoetis MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 35.7% Upside
$221.14 Price Target
Short Interest: Healthy
0.80% of Float Sold Short
Dividend Strength: Moderate
Based on Four Factors
Sustainability: -4.66
Upright™ Environmental Score
News Sentiment: 0.43
Based on 12 Articles This Week
Insider Trading: Selling Shares
$763,228 Sold Last Quarter
Proj. Earnings Growth: 10.56%
From $5.40 to $5.97 Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.89 out of 5 stars

Medical Sector

37th out of 1,006 stocks

Pharmaceutical Preparations Industry

15th out of 492 stocks

3.5

Analyst's Opinion

Consensus Rating
Zoetis has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 8 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $221.14, Zoetis has a forecasted upside of 35.7% from its current price of $163.01.
Amount of Analyst Coverage
Zoetis has only been the subject of 1 research reports in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
0.80% of the float of Zoetis has been sold short.
Short Interest Ratio / Days to Cover
Zoetis has a short interest ratio ("days to cover") of 2, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Zoetis has recently decreased by 18.46%, indicating that investor sentiment is improving significantly.

2.5

Dividend Strength

Dividend Yield
Zoetis has a dividend yield of 0.91%, which is in the bottom 25% of all stocks that pay dividends.
Dividend Growth
Zoetis has been increasing its dividend for 9 years.
Dividend Coverage
The dividend payout ratio of Zoetis is 33.86%. This payout ratio is at a healthy, sustainable level, below 75%.
Dividend Sustainability
Based on earnings estimates, Zoetis will have a dividend payout ratio of 25.13% next year. This indicates that Zoetis will be able to sustain or increase its dividend.

0.4

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Zoetis has received a -79.93% net impact score from Upright. The largest negative impact of Zoetis in category "GHG emissions" seems to be driven mostly by its "Cattle antibiotics", "Cattle vaccines", "Vaccines for pet animals", "Antibiotics for pet animals", and "Cattle dewormers" products. See details.
Environmental Sustainability
The Environmental Impact score for Zoetis is -4.66.

3.0

News and Social Media Coverage

News Sentiment
Zoetis has a news sentiment score of 0.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.78 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 12 news articles for Zoetis this week, compared to 6 articles on an average week.
Search Interest
116 people have searched for ZTS on MarketBeat in the last 30 days. This is an increase of 152% compared to the previous 30 days.
MarketBeat Follows
15 people have added Zoetis to their MarketBeat watchlist in the last 30 days. This is an increase of 88% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Zoetis insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $763,228.00 in company stock.
Percentage Held by Insiders
Only 0.15% of the stock of Zoetis is held by insiders.
Percentage Held by Institutions
90.23% of the stock of Zoetis is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

2.5

Earnings and Valuation

Earnings Growth
Earnings for Zoetis are expected to grow by 10.56% in the coming year, from $5.40 to $5.97 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Zoetis is 36.80, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 138.56.
Price to Earnings Ratio vs. Sector
The P/E ratio of Zoetis is 36.80, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 127.65.
Price to Earnings Growth Ratio
Zoetis has a PEG Ratio of 2.66. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
Zoetis has a P/B Ratio of 16.77. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Zoetis (NYSE:ZTS) Stock

Zoetis, Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health technology. The firm operates through the United States and International geographical segments. The United States segment is involved in U.S. market and regulatory activities. The International segment includes non-U.S. market and regulatory activities. The company was founded in 1952 and is headquartered in Parsippany, NJ.

Receive ZTS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Zoetis and its competitors with MarketBeat's FREE daily newsletter.

ZTS Stock News Headlines

May 18, 2023 | marketbeat.com

Zoetis Declares New Dividend, Hinting At Undervaluation (ZTS)

Zoetis shareholders woke up to news of JAB's acquisition of Pumpkin, a per insurance platform where Zoetis owns a minority stake. 2023 outlooks suggest a rally

May 30, 2023 | finance.yahoo.com

Zoetis to Participate in the Stifel 2023 Jaws and Paws Conference

June 1, 2023 | Legacy Research (Affiliate) (Ad)

“You need at least $100 of this asset – and it’s NOT gold” – Dr. Nomi Prin

$100 is all you need… Former Goldman Sachs managing director Dr. Nomi Prins has identified an investment she’s calling ‘the world’s hardest asset’ – and she’s recommending it to friends, family, and followers.

May 29, 2023 | benzinga.com

$1000 Invested In This Stock 10 Years Ago Would Be Worth $5,000 Today

May 28, 2023 | americanbankingnews.com

Analysts Set Zoetis Inc. (NYSE:ZTS) PT at $221.14

May 28, 2023 | americanbankingnews.com

Analysts Set Zoetis Inc. (NYSE:ZTS) Target Price at $221.14

May 26, 2023 | msn.com

Atlantic Equities Reiterates Zoetis Inc - (ZTS) Overweight Recommendation

May 25, 2023 | cnbc.com

Zoetis CEO Kristin Peck sits down with Jim Cramer

June 1, 2023 | Legacy Research (Affiliate) (Ad)

“One-Stock Millionaire” IGNORES 99.9% of the Market

During the 2008 financial crisis, millionaire trader Jeff Clark stunned the world when he managed to double his readers’ money 26 TIMES… CNBC caught wind of this and asked Jeff to come on live TV to explain his secret.

May 25, 2023 | finance.yahoo.com

Zoetis Holds Investor Day and Presents Strategy to Shape Animal Health for the Next Decade

May 21, 2023 | fool.com

Zoetis (NYSE: ZTS)

May 19, 2023 | americanbankingnews.com

Zoetis (NYSE:ZTS) Now Covered by Analysts at StockNews.com

May 18, 2023 | finance.yahoo.com

Multiple Reasons for the Outperformance of Zoetis (ZTS)

May 16, 2023 | businesswire.com

JAB’s Pet Insurance Platform Acquires Pumpkin, Expanding its Global Leadership in the Fast-Growing Pet Insurance Industry

May 15, 2023 | msn.com

Zoetis's Return On Capital Employed Overview

May 13, 2023 | msn.com

Zoetis Inc - (ZTS) Declares $0.38 Dividend

May 11, 2023 | msn.com

Zoetis declares $0.375 dividend

May 11, 2023 | msn.com

Here's How Much $100 Invested In Zoetis 10 Years Ago Would Be Worth Today

May 11, 2023 | finance.yahoo.com

Zoetis Declares Third Quarter 2023 Dividend

May 11, 2023 | americanbankingnews.com

Zoetis (NYSE:ZTS) Price Target Lowered to $210.00 at Piper Sandler

May 10, 2023 | msn.com

Zoetis' Dividend Growth: Small Yield, Big Returns

May 9, 2023 | finance.yahoo.com

Zoetis Shares Are Barking Up the Right Tree

May 9, 2023 | americanbankingnews.com

Zoetis Inc. to Post Q2 2023 Earnings of $1.32 Per Share, William Blair Forecasts (NYSE:ZTS)

May 8, 2023 | markets.businessinsider.com

Piper Sandler Reaffirms Their Buy Rating on Zoetis (ZTS)

May 8, 2023 | markets.businessinsider.com

Zoetis' Osteoarthritis Med for Dogs Set to Deliver Significant Advantages In 2024, Analyst Says

May 8, 2023 | msn.com

Piper Sandler Maintains Zoetis Inc - (ZTS) Overweight Recommendation

May 7, 2023 | americanbankingnews.com

Zoetis (NYSE:ZTS) Sets New 1-Year High on Strong Earnings

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive ZTS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Zoetis and its competitors with MarketBeat's FREE daily newsletter.

ZTS Company Calendar

Ex-Dividend for 6/1 Dividend: 4/20/2023
Last Earnings: 5/04/2023
Today: 6/01/2023
Dividend Payable: 6/01/2023
Next Earnings (Estimated): 8/03/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NYSE
Industry: Pharmaceutical preparations
Sub-Industry: Pharmaceuticals
Sector: Medical
Current Symbol: NYSE:ZTS
CUSIP: 98978V10
CIK: 1555280
Web: www.zoetis.com
Phone: (973) 822-7000
Fax: 302-655-5049
Employees: 13,800
Year Founded: 2012

Price Target and Rating

Average Stock Price Forecast: $221.14
High Stock Price Forecast: $260.00
Low Stock Price Forecast: $180.00
Forecasted Upside/Downside: +35.7%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 8 Analysts

Profitability

EPS (Most Recent Fiscal Year): $4.43
Trailing P/E Ratio: 36.80
Forward P/E Ratio: 30.19
P/E Growth: 2.66
Net Income: $2.11 billion
Net Margins: 25.59%
Pretax Margin: 32.44%
Return on Equity: 50.26%
Return on Assets: 16.24%

Debt

Debt-to-Equity Ratio: 1.46
Current Ratio: 3.27
Quick Ratio: 1.94

Sales & Book Value

Annual Sales: $8.08 billion
Price / Sales: 9.32
Cash Flow: $5.86 per share
Price / Cash Flow: 27.80
Book Value: $9.72 per share
Price / Book: 16.77

Miscellaneous

Outstanding Shares: 462,110,000
Free Float: 461,419,000
Market Cap: $75.33 billion
Optionable: Optionable
Beta: 0.77

Social Links

Key Executives

Kristin C. Peck
Chief Executive Officer & Director

Roxanne Lagano
Chief Human Resources Officer & Executive VP

Wetteny Joseph
CFO, EVP & Head-Business Development

Mike McFarland
Chief Medical Officer & Executive Vice President

Robert J. Polzer
President-Research & Development, Executive VP

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

ZTS Stock - Frequently Asked Questions

Should I buy or sell Zoetis stock right now?: 8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Zoetis in the last twelve months. There are currently 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ZTS shares.
View ZTS analyst ratings or view top-rated stocks.
What is Zoetis' stock price forecast for 2023?: 8 equities research analysts have issued 12 month target prices for Zoetis' shares. Their ZTS share price forecasts range from $180.00 to $260.00. On average, they anticipate the company's stock price to reach $221.14 in the next year. This suggests a possible upside of 35.7% from the stock's current price.
View analysts price targets for ZTS or view top-rated stocks among Wall Street analysts.
How have ZTS shares performed in 2023?: Zoetis' stock was trading at $146.55 on January 1st, 2023. Since then, ZTS stock has increased by 11.2% and is now trading at $163.01.
View the best growth stocks for 2023 here.
Are investors shorting Zoetis?: Zoetis saw a decline in short interest in May. As of May 15th, there was short interest totaling 3,710,000 shares, a decline of 18.5% from the April 30th total of 4,550,000 shares. Based on an average daily trading volume, of 1,830,000 shares, the days-to-cover ratio is currently 2.0 days. Approximately 0.8% of the company's shares are sold short.
View Zoetis' Short Interest.
When is Zoetis' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023.
View our ZTS earnings forecast.
How were Zoetis' earnings last quarter?: Zoetis Inc. (NYSE:ZTS) issued its earnings results on Thursday, May, 4th. The company reported $1.31 earnings per share for the quarter, topping analysts' consensus estimates of $1.27 by $0.04. The business had revenue of $2 billion for the quarter, compared to analyst estimates of $2.02 billion. Zoetis had a net margin of 25.59% and a trailing twelve-month return on equity of 50.26%. The business's revenue for the quarter was up .7% compared to the same quarter last year. During the same quarter in the prior year, the company earned $1.32 EPS.
Read the conference call transcript.
How often does Zoetis pay dividends? What is the dividend yield for Zoetis?: Zoetis declared a quarterly dividend on Thursday, May 11th. Investors of record on Friday, July 21st will be given a dividend of $0.375 per share on Friday, September 1st. This represents a $1.50 annualized dividend and a dividend yield of 0.92%. The ex-dividend date is Thursday, July 20th.
Read our dividend analysis for ZTS.
What ETFs hold Zoetis' stock?: ETFs with the largest weight of Zoetis (NYSE:ZTS) stock in their portfolio include ProShares Pet Care ETF (PAWZ), VanEck Agribusiness ETF (MOO), IQ Winslow Focused Large Cap Growth ETF (IWFG), SPDR S&P Pharmaceuticals ETF (XPH), iShares U.S. Pharmaceuticals ETF (IHE), VanEck Pharmaceutical ETF (PPH), First Trust Nasdaq Pharmaceuticals ETF (FTXH) and Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL).
Is Zoetis a good dividend stock?: Zoetis (NYSE:ZTS) pays an annual dividend of $1.50 per share and currently has a dividend yield of 0.91%. The company has been increasing its dividend for 9 consecutive years, indicating the company has a new, but growing committment to grow its dividend. The dividend payout ratio is 33.86%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, ZTS will have a dividend payout ratio of 25.13% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for ZTS.
What guidance has Zoetis issued on next quarter's earnings?: Zoetis issued an update on its FY 2023 earnings guidance on Thursday, May, 4th. The company provided earnings per share (EPS) guidance of $5.34-$5.44 for the period, compared to the consensus EPS estimate of $5.40. The company issued revenue guidance of $8.57 billion-$8.72 billion, compared to the consensus revenue estimate of $8.65 billion.

What is Kristin Peck's approval rating as Zoetis' CEO?: 50 employees have rated Zoetis Chief Executive Officer Kristin Peck on Glassdoor.com. Kristin Peck has an approval rating of 82% among the company's employees. 70.0% of employees surveyed would recommend working at Zoetis to a friend.
What other stocks do shareholders of Zoetis own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Zoetis investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), Hawkins (HWKN), Aegean Marine Petroleum Network (ANW), Athabasca Oil (ATH), Micron Technology (MU), Accenture (ACN) and Transocean (RIG).
What is Zoetis' stock symbol?: Zoetis trades on the New York Stock Exchange (NYSE) under the ticker symbol "ZTS."
Who are Zoetis' major shareholders?: Zoetis' stock is owned by a number of retail and institutional investors. Top institutional investors include BlackRock Inc. (8.63%), State Street Corp (4.20%), Wellington Management Group LLP (2.60%), Price T Rowe Associates Inc. MD (2.22%), Geode Capital Management LLC (2.11%) and FMR LLC (1.74%). Insiders that own company stock include Catherine A Knupp, Glenn David, Gregory Norden, Heidi C Chen, Juan Ramon Alaix, Kristin C Peck, Linda Rhodes, Robert Edward Kelly, Robert W Scully, Roman Trawicki, Roxanne Lagano and Willie M Reed.
View institutional ownership trends.
How do I buy shares of Zoetis?: Shares of ZTS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Zoetis' stock price today?: One share of ZTS stock can currently be purchased for approximately $163.01.
How much money does Zoetis make?: Zoetis (NYSE:ZTS) has a market capitalization of $75.33 billion and generates $8.08 billion in revenue each year. The company earns $2.11 billion in net income (profit) each year or $4.43 on an earnings per share basis.
How many employees does Zoetis have?: The company employs 13,800 workers across the globe.
Does Zoetis have any subsidiaries?: The following companies are subsidiares of Zoetis: Abaxis, Abaxis Asia Limited, Abaxis Europe GmbH, Abaxis Inc., Abaxis South East Europe d. o.o., Abaxis UK Limited, Alpharma Animal Health Company, Alpharma Animal Health Hong Kong Co. Limited, Alpharma Bermuda LLC, Alpharma Euro Holdings LLC, Alpharma Holdings Barbados SRL, Alpharma LLC, Alpharma Luxembourg S.A.R.L. y Compania Limitada, Alpharma do Brasil Ltda., Bovigen, Catapult Genetics Pty Ltd, Continental Farmaceutica SPRL, Cross Vetpharm Group Limited, Embrex LLC, Ethos Diagnostic Science, Fish Vet Group, Fish Vet Group Limited, Jilin Zoetis Guoyuan Animal Health Co. Ltd., Jorox Pty, King Animal Health, Microtek International Inc, Mikjan Corporation, Nexvet, Nexvet Australia Pty Ltd, PAH 7V6 Holding Limited, PAH CHHK Holding B.V., PAH India Holdco LLC, PAH India Holding 1 B.V., PAH Netherlands 2 B.V., PAH Oceania B.V., PAH Spain S.L., PHARMAQ, PT Zoetis Animalhealth Indonesia, Performance Livestock Analytics, Performance Livestock Analytics Inc., Pharmaq AS Chile Limitada, Pharmaq AS Service SpA, Pharmaq AS., Pharmaq Analytiq AS, Pharmaq Analytiq Limited, Pharmaq Analytiq SpA, Pharmaq Fishteq AS, Pharmaq Fishteq SpA, Pharmaq Ltd, Pharmaq Spain Aqua SL, Pharmaq Veterinar Ecza Deposu ve su Urunleri Ticaret Ltd Ski, Pharmaq Vietnam Company Limited, Phoenix Central Laboratory for Veterinarians Inc., Phoenix Lab, Platinum Performance, Platinum Performance Inc., Pumpkin Holdings Inc., Pumpkin Insurance Services Inc., Scandinavian Micro Biodevices, Smartbow GmbH, Smartbow RUS OOO, Synbiotics Corporation, Synbiotics LLC, Vetnex Animal Health Ltd, Virtual Recall, Virtual Recall Limited, Virtual Recall Pty Ltd, ZNLabs, ZNLabs LLC, ZOETISECUADOR Cia. Ltda., Zoetis Animal Health ApS, Zoetis Argentina S.R.L., Zoetis Australia Pty Ltd, Zoetis Australia Research & Manufacturing Pty Ltd, Zoetis B.V., Zoetis Belgium S.A., Zoetis Biopharmaceutical Co. Ltd, Zoetis Broomhill IP Limited, Zoetis Broomhill Property Limited, Zoetis C.A., Zoetis Canada Inc., Zoetis Colombia S.A.S., Zoetis Costa Rica S.R.L., Zoetis Denmark ApS, Zoetis Deutschland GmbH, Zoetis Egypt LLC, Zoetis Egypt Pharmaceuticals LLC, Zoetis Egypt Trading LLC, Zoetis Enterprise Management Shanghai Co. Ltd., Zoetis Finland Oy, Zoetis France, Zoetis Hayvan Sagligi Ltd. Sti., Zoetis Hellas S.A., Zoetis Holdings LLC, Zoetis Hungary Kft., Zoetis Import Egypt LLC, Zoetis India Limited, Zoetis Indústria de Produtos Veterinários Ltda., Zoetis International Holdings B.V., Zoetis Israël Holding B.V., Zoetis Italia S.r.l., Zoetis Japan K.K., Zoetis Korea Ltd., Zoetis LLC, Zoetis Luxembourg Holding S.à r.l., Zoetis Malaysia Sdn. Bhd., Zoetis Manufacturing & Research Spain S.L., Zoetis Manufacturing Italia S.R.L., Zoetis Medolla Manufacturing S.R.L., Zoetis Mexico S. de R.L. de C.V., Zoetis Netherlands 1 B.V., Zoetis Netherlands 3 B.V., Zoetis Netherlands 4 B.V., Zoetis Netherlands 5 B.V., Zoetis New Zealand Limited, Zoetis OOO, Zoetis Overseas Holding B.V., Zoetis Overseas Services Inc., Zoetis Panama S. de R.L., Zoetis Pharmaceutical Research Private Limited, Zoetis Philippines Inc., Zoetis Polska sp. z o.o, Zoetis Portugal Lda., Zoetis Products Inc., Zoetis Reference Laboratories China Co. Ltd., Zoetis Reference Labs LLC, Zoetis Romania SRL, Zoetis S.R.L., Zoetis Salud Animal de Bolivia S.A., Zoetis Schweiz GmbH, Zoetis Services LLC, Zoetis Singapore Pte. Ltd., Zoetis South Africa Pty Ltd., Zoetis Spain S.L., Zoetis Subsidiary Holdings Inc., Zoetis Suzhou Manufacturing Co. Ltd., Zoetis Sweden AB, Zoetis Taiwan Limited, Zoetis Thailand Limited, Zoetis Treasury Center BV, Zoetis UK Limited, Zoetis US LLC, Zoetis Ukraine LLC, Zoetis Vietnam Limited Liability Company, Zoetis WLC LLC, Zoetis Weesp B.V., Zoetis Yantai Manufacturing Co. Ltd., Zoetis de Chile S.A., Zoetis de Uruguay S.R.L., Zoetis Österreich GmbH, and Zoetis Česká republika s.r.o..
Read More
How can I contact Zoetis?: Zoetis' mailing address is 10 Sylvan Way, Parsippany NJ, 07054. The official website for the company is www.zoetis.com. The company can be reached via phone at (973) 822-7000, via email at steve.frank@zoetis.com, or via fax at 302-655-5049.

This page (NYSE:ZTS) was last updated on 6/1/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial